Home LiteratureArticle Details
PMID: 10984324 Published · ppublish English Journal Article Review

Mechanisms of action and resistance of older and newer fluoroquinolones.

Hooper DC

Abstract

The fluoroquinolones interact with 2 bacterial targets, the related enzymes DNA gyrase and topoisomerase IV, both of which are involved in DNA replication. Quinolones form complexes of these enzymes with DNA, complexes that block movement of the DNA-replication fork and thereby inhibit DNA replication. Many older quinolones differ in their relative activities against gyrase and topoisomerase IV in a bacterial cell, having greater potency against gyrase than against topoisomerase IV in many gram-negative bacteria and greater potency against topoisomerase IV than against gyrase in many gram-positive bacteria. Several newer quinolones appear to have more closely balanced activity against these enzymes. Resistance to fluoroquinolones occurs as a result of mutational amino acid substitutions in the subunits of the more sensitive (or primary-target) enzyme within the cell. If, however, both enzymes are similarly susceptible to a fluoroquinolone, then the level of resistance caused by a primary-target mutation may be low and may be limited by the sensitivity of the secondary target. Fluoroquinolones also differ in the extent to which common bacterial multidrug efflux pumps affect their activity, with some compounds being unaffected by resistance mechanisms because of overexpression of such pumps. Newer fluoroquinolone interaction with dual targets and avoidance of efflux-resistance mechanisms may each contribute to the lower frequencies of selection of resistant mutants in the laboratory.

MeSH Terms
Anti-Infective Agents/pharmacokinetics,pharmacology Biological Transport, Active DNA Topoisomerase IV DNA Topoisomerases, Type II/genetics Drug Resistance, Microbial/genetics Enzyme Inhibitors/pharmacokinetics,pharmacology Escherichia coli/drug effects,enzymology,genetics Fluoroquinolones Humans In Vitro Techniques Mutation Staphylococcus aureus/drug effects,enzymology,genetics Topoisomerase II Inhibitors
Chemicals
Anti-Infective Agents Enzyme Inhibitors Fluoroquinolones Topoisomerase II Inhibitors DNA Topoisomerase IV DNA Topoisomerases, Type II
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Hooper D C
Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114-2696, USA. [email protected].
Article Info
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Abbr.
Clin Infect Dis
ISSN
1058-4838
Published
2000-08-00
Pages
S24-8
Language
English
Region
United States
NLM ID
9203213
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]